<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Med (Lausanne)</journal-id><journal-id journal-id-type="iso-abbrev">Front Med (Lausanne)</journal-id><journal-id journal-id-type="publisher-id">Front. Med.</journal-id><journal-title-group><journal-title>Frontiers in Medicine</journal-title></journal-title-group><issn pub-type="epub">2296-858X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098573</article-id><article-id pub-id-type="doi">10.3389/fmed.2025.1586068</article-id><article-categories><subj-group subj-group-type="heading"><subject>Medicine</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Inappropriate use of propranolol among medical and dental students at the University of Jordan: cross-sectional study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Taha</surname><given-names>Hana</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><xref rid="fn004" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="http://loop.frontiersin.org/people/1291975/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Awamleh</surname><given-names>Suhib</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn004" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="http://loop.frontiersin.org/people/2991682/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/></contrib><contrib contrib-type="author"><name><surname>Al Tayyeb</surname><given-names>AbdelRahman</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn004" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="http://loop.frontiersin.org/people/3000001/overview"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/></contrib><contrib contrib-type="author"><name><surname>Samhouri</surname><given-names>Salwa</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn004" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="http://loop.frontiersin.org/people/2993114/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Abbasi</surname><given-names>Yousef</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn004" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="http://loop.frontiersin.org/people/2991812/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author"><name><surname>Alwaked</surname><given-names>Lujaien</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="http://loop.frontiersin.org/people/2991908/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>El Jaber</surname><given-names>Aya</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn004" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="http://loop.frontiersin.org/people/3000005/overview"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author"><name><surname>Massad</surname><given-names>Raseel</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Alkhaldi</surname><given-names>Sireen M.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn004" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Family and Community Medicine, School of Medicine, University of Jordan</institution>, <addr-line>Amman</addr-line>, <country>Jordan</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Neurobiology, Care Science and Society, Karolinska Institutet</institution>, <addr-line>Stockholm</addr-line>, <country>Sweden</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Yibo Wu, Peking University, China</p></fn><fn fn-type="edited-by"><p>Reviewed by: Luka &#x00160;imunovi&#x00107;, University of Zagreb, Croatia</p><p>Kadhim Kadhim, University of Basrah, Iraq</p><p>Yusransyah Yusransyah, Salsabila Serang College of Health Sciences, Indonesia</p></fn><corresp id="c001">*Correspondence: Hana Taha, <email>hanagh@yahoo.com</email></corresp><fn fn-type="other" id="fn004"><p><sup>&#x02020;</sup>ORCID: Hana Taha, <ext-link xlink:href="https://orcid.org/0000-0001-8710-8249" ext-link-type="uri">orcid.org/0000-0001-8710-8249</ext-link>; Suhib Awamleh, <ext-link xlink:href="https://orcid.org/0009-0002-6031-6480" ext-link-type="uri">orcid.org/0009-0002-6031-6480</ext-link>; AbdelRahman Al Tayyeb, <ext-link xlink:href="https://orcid.org/0009-0000-6055-7044" ext-link-type="uri">orcid.org/0009-0000-6055-7044</ext-link>; Salwa Samhouri, <ext-link xlink:href="https://orcid.org/0009-0006-1298-2939" ext-link-type="uri">orcid.org/0009-0006-1298-2939</ext-link>; Yousef Abbasi, <ext-link xlink:href="https://orcid.org/0009-0005-1546-7636" ext-link-type="uri">orcid.org/0009-0005-1546-7636</ext-link>; Aya El Jaber, <ext-link xlink:href="https://orcid.org/0009-0009-7912-0577" ext-link-type="uri">orcid.org/0009-0009-7912-0577</ext-link>; Sireen M. Alkhaldi, <ext-link xlink:href="https://orcid.org/0000-0002-7584-4502" ext-link-type="uri">orcid.org/0000-0002-7584-4502</ext-link></p></fn></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>12</volume><elocation-id>1586068</elocation-id><history><date date-type="received"><day>02</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Taha, Awamleh, Al Tayyeb, Samhouri, Abbasi, Alwaked, El Jaber, Massad and Alkhaldi.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Taha, Awamleh, Al Tayyeb, Samhouri, Abbasi, Alwaked, El Jaber, Massad and Alkhaldi</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Aim</title><p>This paper aimed to investigate the prevalence of beta-blocker inappropriate use specifically propranolol, among medical and dental students at the University of Jordan. It examined the patterns of Propranolol consumption for stress management including frequency of usage, dosage, side effects experienced as well as the respondents&#x02019; level of awareness about the risks associated with unsupervised propranolol use.</p></sec><sec><title>Methods</title><p>Cross-sectional study conducted at the University of Jordan in December 2024 and recruited 584 students (418 Medicine, 166 Dentistry). The data were analyzed using SPSS (version 27). Descriptive statistics were used to describe the sample, Pearson&#x02019;s chi-squared test, fisher&#x02019;s exact test, independent samples <italic>t</italic>-test and binary logistic regression model were used to identify the predictors of propranolol use. Statistical significance was set at a <italic>p</italic>-value &#x02264; 0.05.</p></sec><sec><title>Results</title><p>Among the participants, 9.9% of the students reported using propranolol and 44% of the users learned about the medication through the recommendation of their friends and peers. Even though most students (74.1%) were aware of the potential risks of unsupervised propranolol use, still, 58.6% of the users took it without a prescription. The most common reasons for using propranolol were anxiety management (65.5%) and exam stress (60.3%). Most propranolol users (60.3%) noticed improvement in their academic performance and 36.2% of them experienced side effects such as dizziness and fatigue.</p></sec><sec><title>Conclusion</title><p>Self-medication with propranolol among medical students to deal with academic anxiety carries serious risks. The findings of this research necessitate covering the potential hazards of self-prescription with beta-blockers within the curriculum of undergraduate medical and dental students. Moreover, there is a need for implementing student psychosocial support programs to improve their approach to managing stress and academic pressure.</p></sec></abstract><kwd-group><kwd>beta-blockers</kwd><kwd>propranolol</kwd><kwd>medical students</kwd><kwd>dental students</kwd><kwd>self-medication</kwd><kwd>anxiety</kwd><kwd>misuse</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. The authors declare that this research article publication fees were covered under the national open access agreement between Karolinska Institutet; as a member of Sweden&#x02019;s academic consortium Bibsam and Frontiers journals.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="4"/><equation-count count="0"/><ref-count count="41"/><page-count count="10"/><word-count count="6318"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Healthcare Professions Education</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="S1"><title>Introduction</title><p>Propranolol is a beta-adrenergic receptor antagonist that was developed more than 60 years ago (<xref rid="B1" ref-type="bibr">1</xref>). Due to its action on multiple receptor sites, propranolol is used in the treatment of many conditions including hypertension, cardiac arrhythmias, myocardial infarction, migraine, portal hypertension, hyperthyroidism, anxiety, essential tremors, and pheochromocytoma (<xref rid="B2" ref-type="bibr">2</xref>). Propranolol is a non-selective beta-blocker (BB) that blocks the action of catecholamines (adrenaline and noradrenaline) on beta-1 and beta-2 adrenergic receptors which inhibit the sympathetic effects that are activated by those receptors (<xref rid="B3" ref-type="bibr">3</xref>). This results in slowed heart rate, decreased oxygen demand, vasodilation, and reduced blood pressure (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). Certain BBs, such as propranolol are lipophilic, enabling them to cross the blood-brain barrier and exert their effects on the Central Nervous System (CNS) (<xref rid="B6" ref-type="bibr">6</xref>). Through this extended spectrum of activity, it is evident that certain BBs can exhibit anxiolytic effects, which dampen the fight-or-flight response (<xref rid="B7" ref-type="bibr">7</xref>).</p><p>While propranolol may be effective in alleviating anxiety-related symptoms, it is frequently associated with side effects such as fatigue, insomnia, nightmares, dizziness, slow heart rate, and low blood pressure which can be exacerbated in the absence of proper medical supervision (<xref rid="B5" ref-type="bibr">5</xref>). Furthermore, propranolol is associated with potential neuropsychiatric complications (<xref rid="B6" ref-type="bibr">6</xref>). Propranolol is also known to induce depression type of organic mood disorder characterized by fatigue, weakness, and psychomotor retardation (<xref rid="B8" ref-type="bibr">8</xref>). Additionally, lipophilic BBs such as propranolol have been reported to disturb sleep continuity. Though the precise mechanism remains unclear, the study hypothesized it was through attachment to serotonergic receptors, crucial factors in the physiology of normal sleep (<xref rid="B9" ref-type="bibr">9</xref>). This particular side effect may undermine propranolol&#x02019;s ability to reduce stress, as poor sleep is strongly correlated with heightened stress levels (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>Propranolol may affect the metabolism of some medications such as antipyrine, chlorpromazine, theophylline and thyroid hormones (<xref rid="B11" ref-type="bibr">11</xref>). The decrease of plasma Triiodothyronine (T3), could be responsible for some of the metabolic responses to propranolol (<xref rid="B12" ref-type="bibr">12</xref>). A change in diet from high carbohydrates to high protein may result in increased oral clearance (<xref rid="B13" ref-type="bibr">13</xref>). Propranolol should be used with extreme caution in patients with diabetes because it might mask hypoglycemia symptoms including flushing, tachycardia, sweating, and dizziness (<xref rid="B5" ref-type="bibr">5</xref>). Moreover, dosages need to be adjusted to avoid toxicity in case of hepatic or renal insufficiency (<xref rid="B5" ref-type="bibr">5</xref>). Misuse of BBs can lead to serious adverse events and overdose can lead to severe cardiac arrest (<xref rid="B14" ref-type="bibr">14</xref>). Sudden withdrawal of propranolol should be avoided because it can lead to psychosis (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>) and life-threatening rebound angina, arrhythmias and infarction (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>). Ingestion of more than 1 g of propranolol in 24 h could be fatal and could lead to lethal bradycardia, bradyarrhythmia, hypotension, bronchospasm (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>The ethical and legal implications of using propranolol in academic settings for performance anxiety are overlooked and understudied (<xref rid="B19" ref-type="bibr">19</xref>). Although propranolol is not approved by the American Food and Drug Administration (FDA) as anxiolytic, still it is procured in many countries over the counter (OTC), probably because it is perceived as a medication without abuse potential (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>). BBs are often used off-label by students experiencing exams-related stress (<xref rid="B21" ref-type="bibr">21</xref>). Butt et al., found that students who take BBs before exams had a significantly higher risk of taking antidepressants and a higher rate of suicide in the future (<xref rid="B21" ref-type="bibr">21</xref>). Thus, propranolol self-medication can be a warning sign about the more vulnerable students with psychological issues who need care.</p><p>Previous literature from Saudi Arabia have explored the prevalence of BBs inappropriate use among medical and dental students (<xref rid="B22" ref-type="bibr">22</xref>&#x02013;<xref rid="B27" ref-type="bibr">27</xref>). A study conducted among Saudi medical and dental students found 30% use of propranolol (Inderal<sup>&#x000ae;</sup>) among the participants. Females and junior students from both specialties were less likely to use propranolol, whereas medical students were more likely to be propranolol users (<xref rid="B24" ref-type="bibr">24</xref>). Another study conducted by Abukhalaf et.al., in King Saud University found 22.4% prevalence of using BBs and 13.9% self-medication with BBs among medical and dental students. The most common reason for using BBs was to relieve stress and anxiety (<xref rid="B25" ref-type="bibr">25</xref>). A cross-sectional study was conducted at the College of Medicine, Taibah University, Al-Madinah Al-Munawwarah, Saudi Arabia found that 9.3% of the medical students used BBs during final exams and 76% of the BBs users were self-medicated without medical supervision (<xref rid="B27" ref-type="bibr">27</xref>).</p><p>A study conducted at the University of Jordan by Toubasi et al., found that 66.3% of medical students felt stressed (<xref rid="B10" ref-type="bibr">10</xref>). Another study conducted in Jordan by Masri et al., showed that medical students suffer from a high level of exhaustion (91%), disengagement (87%) and &#x0201c;minor&#x0201d; psychiatric illness (92%) (<xref rid="B28" ref-type="bibr">28</xref>). However, there is no research about the inappropriate use of Propranolol among medical students in Jordan. Thus, this is the first study that aims to investigate the prevalence of inappropriate use of BBs, specifically propranolol, among medical and dentistry students at the University of Jordan. It will also examine the patterns of propranolol consumption for stress management within this population, as well as assess the respondents&#x02019; level of knowledge regarding the risks associated with unsupervised propranolol use.</p></sec><sec sec-type="materials|methods" id="S2"><title>Materials and methods</title><sec id="S2.SS1"><title>Study design</title><p>This is a quantitative Cross-sectional study conducted in the School of Medicine at the University of Jordan from November 4 to December 14, 2024. The data was collected using voluntary anonymous self-administered online structured questionnaire.</p></sec><sec id="S2.SS2"><title>Study setting</title><p>Medical education in Jordan has developed significantly in recent decades. There are currently 8 medical schools in Jordan (2 private and 6 public) (<xref rid="B29" ref-type="bibr">29</xref>). The estimated total number of medical students in Jordan is 10,000, with approximately 1,500 graduates per year (<xref rid="B29" ref-type="bibr">29</xref>). The School of Medicine at the University Jordan was established in 1971. It is the first, the most prestigious and the top ranked college of medicine in the kingdom (<xref rid="B30" ref-type="bibr">30</xref>). There are 5,200 students enrolled with 69% females and 31% males (<xref rid="B30" ref-type="bibr">30</xref>). The academic year distribution includes 7.69% in the first year, 12.50% in the second year, 25.96% in the third year, 15.38% in the fourth year, 23.07% in the fifth year, and 15.38% in the sixth year. This distribution was considered when evaluating the representativeness of the sample.</p></sec><sec id="S2.SS3"><title>Measurement tool</title><p>A structured questionnaire was constructed based on pre-validated questionnaires from existing literature (<xref rid="B24" ref-type="bibr">24</xref>&#x02013;<xref rid="B26" ref-type="bibr">26</xref>). However, the final set of questions were formulated by the authors and to ensure its relevance for our study population, the questionnaire underwent validation through content and face validity (<xref rid="B31" ref-type="bibr">31</xref>). The process involved the feedback of three experts in the fields of epidemiology and pharmacology. A pilot study was conducted with a sample size of <italic>N</italic> (138) to further reaffirm the relevance and validity of the questionnaire. The questionnaire consisted of 34 questions divided into five main segments. The sections included the following:</p><p>The first section captured sociodemographic characteristics, behavioral determinants of managing stress and past medical history. Sociodemographic information included: Age, gender, place of residence, year and program of study, weight and height. The behavioral determinants outlined the patterns of exercise, caffeine consumption, smoking and hours of sleep before examination. The second section focused on the usage of propranolol and how the participants firstly heard about propranolol and whether they were taking propranolol under a medical prescription. The third section further elaborated on the patterns of usage, frequency of usage, primary reason behind using propranolol and a question to indicate if participants notice academic improvement when using propranolol. The fourth section illustrated the doses of propranolol used and the approach of consuming propranolol before a stressful event. The final section assed the experienced side effects of propranolol and the extent of awareness regarding the side effects.</p></sec><sec id="S2.SS4"><title>Sample size and data collection</title><p>Convenience sampling was used as an appropriate method of recruiting participants due to feasibility and practicality of reaching the targeted population, as well as cost-effectiveness. Convenience sampling might impose certain limitation; however, this method was deemed suitable to answer the research question and any potential drawbacks are discussed in the limitations section.</p><p>The estimated sample size needed for this study was 357 participant and this was calculated using Cochran&#x02019;s formula <italic>N</italic> = (Z<sup>2</sup> p q)/e<sup>2</sup> where, <italic>N</italic> is the sample size, <italic>Z</italic> is the <italic>Z</italic>-score statistic for 95% level of confidence which is 1.96, <italic>P</italic> is the expected prevalence which was estimated to be 18.06% based on approximating the mean prevalence from previous studies conducted in Saudia Arabia with similar populations (<xref rid="B22" ref-type="bibr">22</xref>&#x02013;<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B32" ref-type="bibr">32</xref>) and the margin of error = 0.05 (<xref rid="B33" ref-type="bibr">33</xref>). However, we recruited in this study a total of 584 students to ensure broader representation.</p><p>The questionnaire was placed on a Google form and was disseminated online through medical and dental students&#x02019; Facebook and WhatsApp groups. The inclusion criteria in this study were full-time undergraduate medical students from years 1-6 and dental students from years 1 to 5 at the University of Jordan aged 18&#x02013;26. A total of 591 responses were recorded for the online questionnaire. However, 5 responses were excluded due to the refusal of consent to participation. Additionally, 2 responses presented with irreconcilable data were also excluded. These exclusions were made when responses were incomplete to the extent that essential variables required for analysis were missing or when contradictory information was provided, making it impossible to interpret or validate the data. The final data set was composed of <italic>N</italic> (584) students (418 Medicine, 166 Dentistry).</p></sec><sec id="S2.SS5"><title>Data analysis</title><p>Statistical Package for the Social Sciences (SPSS) version 27 was used to conduct the data analysis. The data collected in this research is discrete in nature, specifically focusing on the prevalence and perception of propranolol. To compare categorical variables between groups, Pearson&#x02019;s Chi-squared tests were used. Fisher&#x02019;s Exact Test (2-sided) was applied in cases where the expected frequency in any cell was less than 5 (specifically for smoking hookah status) and for &#x0201c;Knowledge of propranolol effect on stress and anxiety,&#x0201d; due to highly skewed distribution despite sufficient expected counts. Independent samples <italic>t</italic>-test was performed to investigate the correlation between a continuous variable and a binary variable. For GPA-related analyses, first-year students were excluded as their GPA data was unavailable. However, first-year students were included in all other analyses to ensure a comprehensive representation of academic years. A multivariate analysis was conducted using binary logistic regression model to identify predictors while accounting for potential confounders. The analysis included variables that were selected based on their significance at the bivariate level, as well as variables that were considered clinically or theoretically relevant based on previous research (<xref rid="B22" ref-type="bibr">22</xref>&#x02013;<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B32" ref-type="bibr">32</xref>). Additionally, variables identified as potential confounders, based on their established association with both the outcome and exposure regardless of bivariate significance. Results were reported as odds ratios (ORs) with 95% confidence intervals (CIs). Statistical significance was set at a <italic>p</italic>-value &#x02264; 0.05.</p><p>To check the internal reliability, we conducted Cronbach&#x02019;s Alpha for a single-factor scale. The analysis yielded an Alpha value of 0.816, indicating good internal consistency. Since the questionnaire items used different response scales, the Standardized Cronbach&#x02019;s Alpha was also measured, which came back as 0.946, indicating excellent reliability.</p></sec><sec id="S2.SS6"><title>Ethical considerations</title><p>Ethical approval to conduct the study was obtained from the University of Jordan Institutional Review Board (IRB) (Approval number 19/2024/781). The research adhered to strict ethical guidelines, with all participants giving their consent prior to their involvement in the study. Collected data was anonymized protecting participants identities.</p></sec></sec><sec sec-type="results" id="S3"><title>Results</title><sec id="S3.SS1"><title>Baseline characteristics</title><p>The baseline characteristics of the 584 study participants were analyzed and demonstrated in <xref rid="T1" ref-type="table">Table 1</xref>. The mean age of the participants was 21.21. More than half of the participants were females (66%).</p><table-wrap position="float" id="T1"><label>TABLE 1</label><caption><p>Baseline characteristics.</p></caption><table frame="box" rules="all" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">Variable</td><td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">Category</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">
<italic>N</italic>
</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">%</td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age</td><td valign="top" align="left" rowspan="1" colspan="1">Mean (&#x000b1; SD)</td><td valign="top" align="center" rowspan="1" colspan="1">21.21</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x000b1; 1.592)</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Gender</td><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1">199</td><td valign="top" align="center" rowspan="1" colspan="1">34</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="center" rowspan="1" colspan="1">385</td><td valign="top" align="center" rowspan="1" colspan="1">66</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Program</td><td valign="top" align="left" rowspan="1" colspan="1">Medicine</td><td valign="top" align="center" rowspan="1" colspan="1">418</td><td valign="top" align="center" rowspan="1" colspan="1">71.6</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Dentistry</td><td valign="top" align="center" rowspan="1" colspan="1">166</td><td valign="top" align="center" rowspan="1" colspan="1">28.4</td></tr><tr><td valign="top" align="left" rowspan="6" colspan="1">Academic level</td><td valign="top" align="left" rowspan="1" colspan="1">First year</td><td valign="top" align="center" rowspan="1" colspan="1">25</td><td valign="top" align="center" rowspan="1" colspan="1">4.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Second year</td><td valign="top" align="center" rowspan="1" colspan="1">68</td><td valign="top" align="center" rowspan="1" colspan="1">11.6</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Third year</td><td valign="top" align="center" rowspan="1" colspan="1">155</td><td valign="top" align="center" rowspan="1" colspan="1">26.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fourth year</td><td valign="top" align="center" rowspan="1" colspan="1">88</td><td valign="top" align="center" rowspan="1" colspan="1">15.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fifth year</td><td valign="top" align="center" rowspan="1" colspan="1">146</td><td valign="top" align="center" rowspan="1" colspan="1">25.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sixth year</td><td valign="top" align="center" rowspan="1" colspan="1">102</td><td valign="top" align="center" rowspan="1" colspan="1">17.5</td></tr><tr><td valign="top" align="left" rowspan="3" colspan="1">Smoking (cigarettes</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">43</td><td valign="top" align="center" rowspan="1" colspan="1">7.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">541</td><td valign="top" align="center" rowspan="1" colspan="1">92.6</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mean (for cigarettes per day) (&#x000b1; SD)</td><td valign="top" align="center" rowspan="1" colspan="1">10.47</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x000b1; 7.742)</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Smoking (hookah)</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">35</td><td valign="top" align="center" rowspan="1" colspan="1">6.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">549</td><td valign="top" align="center" rowspan="1" colspan="1">94.0</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Smoking (vape or e-cigs)</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">58</td><td valign="top" align="center" rowspan="1" colspan="1">9.9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">526</td><td valign="top" align="center" rowspan="1" colspan="1">90.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GPA</td><td valign="top" align="left" rowspan="1" colspan="1">Mean (&#x000b1; SD)</td><td valign="top" align="center" rowspan="1" colspan="1">3.39</td><td valign="top" align="center" rowspan="1" colspan="1">(&#x000b1; 0.406)</td></tr><tr><td valign="top" align="left" rowspan="3" colspan="1">Chronic diseases</td><td valign="top" align="left" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">532</td><td valign="top" align="center" rowspan="1" colspan="1">91.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Migraine</td><td valign="top" align="center" rowspan="1" colspan="1">25</td><td valign="top" align="center" rowspan="1" colspan="1">4.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Other</td><td valign="top" align="center" rowspan="1" colspan="1">27</td><td valign="top" align="center" rowspan="1" colspan="1">4.6</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Propranolol use</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">58</td><td valign="top" align="center" rowspan="1" colspan="1">9.9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">526</td><td valign="top" align="center" rowspan="1" colspan="1">90.1</td></tr></tbody></table></table-wrap><p>The highest proportion of participants were in their third year (26.5%), followed by 25.0% in their fifth year. The mean GPA score was found to be 3.39/4.00, excluding the first-year students as at the time of the study, they still didn&#x02019;t receive their GPA. The most common chronic disease affecting the participants was found to be migraine (4.3%). Approximately 10% (<italic>n</italic> = 58) of the participants were propranolol users and none of them were in their first year.</p></sec><sec id="S3.SS2"><title>Factors associated with propranolol use</title><p>Academic level, use of vapes/e-cigarettes, coffee and energy drinks consumption, and the knowledge of propranolol&#x02019;s effect on stress and anxiety were all found to be significantly associated with propranolol use among the study participants. <xref rid="T2" ref-type="table">Table 2</xref> shows the results of different chi-square tests that were conducted to assess the different variables associated with the use of propranolol.</p><table-wrap position="float" id="T2"><label>TABLE 2</label><caption><p>Factors associated with propranolol off-label use.</p></caption><table frame="box" rules="all" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1"/><td valign="top" align="center" colspan="7" style="color:#ffffff;background-color: #7f8080;" rowspan="1">Have you ever used propranolol?</td></tr></thead><tbody><tr><td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">
<bold>Variable</bold>
</td><td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">
<bold>Categories</bold>
</td><td valign="top" align="center" colspan="2" style="color:#ffffff;background-color: #7f8080;" rowspan="1">
<bold>No</bold>
</td><td valign="top" align="center" colspan="2" style="color:#ffffff;background-color: #7f8080;" rowspan="1">
<bold>Yes</bold>
</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">
<bold>&#x003c7;<sup>2</sup></bold>
</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">
<bold><italic>p</italic>-value</bold>
</td></tr><tr><td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1"/><td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1"/><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">
<bold>
<italic>N</italic>
</bold>
</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">
<bold>%</bold>
</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">
<bold>
<italic>N</italic>
</bold>
</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">
<bold>%</bold>
</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1"/><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Gender</td><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="center" rowspan="1" colspan="1">347</td><td valign="top" align="center" rowspan="1" colspan="1">66</td><td valign="top" align="center" rowspan="1" colspan="1">38</td><td valign="top" align="center" rowspan="1" colspan="1">65.5</td><td valign="top" align="center" rowspan="2" colspan="1">0.006</td><td valign="top" align="center" rowspan="2" colspan="1">0.938</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1">179</td><td valign="top" align="center" rowspan="1" colspan="1">34</td><td valign="top" align="center" rowspan="1" colspan="1">20</td><td valign="top" align="center" rowspan="1" colspan="1">34.5</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Program</td><td valign="top" align="left" rowspan="1" colspan="1">Medicine</td><td valign="top" align="center" rowspan="1" colspan="1">372</td><td valign="top" align="center" rowspan="1" colspan="1">70.7</td><td valign="top" align="center" rowspan="1" colspan="1">46</td><td valign="top" align="center" rowspan="1" colspan="1">79.3</td><td valign="top" align="center" rowspan="2" colspan="1">1.939</td><td valign="top" align="center" rowspan="2" colspan="1">0.164</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Dentistry</td><td valign="top" align="center" rowspan="1" colspan="1">154</td><td valign="top" align="center" rowspan="1" colspan="1">29.3</td><td valign="top" align="center" rowspan="1" colspan="1">12</td><td valign="top" align="center" rowspan="1" colspan="1">20.7</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Academic level</td><td valign="top" align="left" rowspan="1" colspan="1">Pre-clinical years</td><td valign="top" align="center" rowspan="1" colspan="1">231</td><td valign="top" align="center" rowspan="1" colspan="1">43.</td><td valign="top" align="center" rowspan="1" colspan="1">17</td><td valign="top" align="center" rowspan="1" colspan="1">29.3</td><td valign="top" align="center" rowspan="2" colspan="1">4.432</td><td valign="top" align="center" rowspan="2" colspan="1">0.035</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Clinical years</td><td valign="top" align="center" rowspan="1" colspan="1">295</td><td valign="top" align="center" rowspan="1" colspan="1">56.1</td><td valign="top" align="center" rowspan="1" colspan="1">41</td><td valign="top" align="center" rowspan="1" colspan="1">70.7</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Smoking (cigarettes)</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">35</td><td valign="top" align="center" rowspan="1" colspan="1">6.7</td><td valign="top" align="center" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">13.8</td><td valign="top" align="center" rowspan="2" colspan="1">4.161</td><td valign="top" align="center" rowspan="2" colspan="1">0.041</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">491</td><td valign="top" align="center" rowspan="1" colspan="1">93.3</td><td valign="top" align="center" rowspan="1" colspan="1">50</td><td valign="top" align="center" rowspan="1" colspan="1">86.2</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Smoking (hookah)</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">32</td><td valign="top" align="center" rowspan="1" colspan="1">6.1</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">5.2</td><td valign="top" align="center" rowspan="2" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="2" colspan="1">1.000<xref rid="t2fna" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">494</td><td valign="top" align="center" rowspan="1" colspan="1">93.9</td><td valign="top" align="center" rowspan="1" colspan="1">55</td><td valign="top" align="center" rowspan="1" colspan="1">94.8</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Smoking (vape/e-cigarettes)</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">48</td><td valign="top" align="center" rowspan="1" colspan="1">9.1</td><td valign="top" align="center" rowspan="1" colspan="1">10</td><td valign="top" align="center" rowspan="1" colspan="1">17.2</td><td valign="top" align="center" rowspan="2" colspan="1">3.801</td><td valign="top" align="center" rowspan="2" colspan="1">0.051</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">478</td><td valign="top" align="center" rowspan="1" colspan="1">90.9</td><td valign="top" align="center" rowspan="1" colspan="1">48</td><td valign="top" align="center" rowspan="1" colspan="1">82.8</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Coffee/energy drinks consumption</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">345</td><td valign="top" align="center" rowspan="1" colspan="1">65.6</td><td valign="top" align="center" rowspan="1" colspan="1">47</td><td valign="top" align="center" rowspan="1" colspan="1">81.0</td><td valign="top" align="center" rowspan="2" colspan="1">5.731</td><td valign="top" align="center" rowspan="2" colspan="1">0.017</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">181</td><td valign="top" align="center" rowspan="1" colspan="1">34.4</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="center" rowspan="1" colspan="1">19.0</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Knowledge of propranolol effect on stress and anxiety</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">322</td><td valign="top" align="center" rowspan="1" colspan="1">61.2</td><td valign="top" align="center" rowspan="1" colspan="1">54</td><td valign="top" align="center" rowspan="1" colspan="1">93.1</td><td valign="top" align="center" rowspan="2" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="2" colspan="1">&#x0003c;0.001<xref rid="t2fna" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">202</td><td valign="top" align="center" rowspan="1" colspan="1">38.8</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">6.9</td></tr></tbody></table><table-wrap-foot><fn id="t2fna"><p><sup>a</sup>Fisher&#x02019;s Exact Test (2-sided) used. For &#x0201c;Smoking (hookah)&#x0201d;, due to low expected cell count; for &#x0201c;Knowledge of propranolol effect on stress and anxiety&#x0201d;, due to highly skewed distribution despite sufficient expected counts.</p></fn></table-wrap-foot></table-wrap><p>A multivariate analysis using binary logistic regression was conducted alongside the Hosmer-Lemeshow test to evaluate the goodness-of-fit of the model used, and it yielded a p-value of 0.127, indicating that the model provides adequate fit to the data. Results of the multivariate analysis are in <xref rid="T3" ref-type="table">Table 3</xref>. We found that cigarette smoking, and coffee consumption were both significantly associated with propranolol use on a bivariate level; but when accounting for other predictors, they were not significant. An independent sample <italic>t</italic>-test revealed that there was no statistically significant relationship between the average hours slept before an exam and propranolol use [<italic>p</italic>-value = 0.136 (95% CI = &#x02212;0.840&#x02013;0.115)].</p><table-wrap position="float" id="T3"><label>TABLE 3</label><caption><p>Multivariate analysis of propranolol use predictors.</p></caption><table frame="box" rules="all" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">Predictor</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">Odds ratio</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">95% CI</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1"><italic>p</italic>-value</td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Gender</td><td valign="top" align="center" rowspan="1" colspan="1">1.151</td><td valign="top" align="center" rowspan="1" colspan="1">0.619&#x02013;2.142</td><td valign="top" align="center" rowspan="1" colspan="1">0.657</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Program</td><td valign="top" align="center" rowspan="1" colspan="1">0.865</td><td valign="top" align="center" rowspan="1" colspan="1">0.430&#x02013;1.740</td><td valign="top" align="center" rowspan="1" colspan="1">0.684</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Academic level (pre <italic>vs.</italic> clinical)</td><td valign="top" align="center" rowspan="1" colspan="1">1.065</td><td valign="top" align="center" rowspan="1" colspan="1">0.563&#x02013;2.016</td><td valign="top" align="center" rowspan="1" colspan="1">0.847</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Smoking cigarettes</td><td valign="top" align="center" rowspan="1" colspan="1">0.480</td><td valign="top" align="center" rowspan="1" colspan="1">0.195&#x02013;1.185</td><td valign="top" align="center" rowspan="1" colspan="1">0.111</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Coffee/energy drinks consumption</td><td valign="top" align="center" rowspan="1" colspan="1">0.497</td><td valign="top" align="center" rowspan="1" colspan="1">0.246&#x02013;1.003</td><td valign="top" align="center" rowspan="1" colspan="1">0.051</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Knowledge of propranolol effect on stress and anxiety</td><td valign="top" align="center" rowspan="1" colspan="1">0.128</td><td valign="top" align="center" rowspan="1" colspan="1">0.043&#x02013;0.375</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GPA</td><td valign="top" align="center" rowspan="1" colspan="1">0.978</td><td valign="top" align="center" rowspan="1" colspan="1">0.693&#x02013;1.382</td><td valign="top" align="center" rowspan="1" colspan="1">0.901</td></tr></tbody></table></table-wrap></sec><sec id="S3.SS3"><title>Propranolol use patterns</title><p>Propranolol users for the most part (44.8%) learned about propranolol through the recommendation of their friends and peers. Around 29.3% reported using it only pre-examinations, with the most common dose being 10 mg (72.4%). Most participants (60.3%) noticed improvements in their academic performance after using propranolol. <xref rid="T4" ref-type="table">Table 4</xref> shows propranolol use pattern, and it demonstrates no statistically significant relationship (<italic>p</italic> = 0.94) between experiencing side effects and the likelihood of recommending propranolol to others.</p><table-wrap position="float" id="T4"><label>TABLE 4</label><caption><p>Propranolol use pattern.</p></caption><table frame="box" rules="all" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">Question</td><td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">Category</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">
<italic>N</italic>
</td><td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;" rowspan="1" colspan="1">%</td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="4" colspan="1">How did you first learn about propranolol?</td><td valign="top" align="left" rowspan="1" colspan="1">Doctor&#x02019;s prescription</td><td valign="top" align="center" rowspan="1" colspan="1">24</td><td valign="top" align="center" rowspan="1" colspan="1">41.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Friend/peer recommendation</td><td valign="top" align="center" rowspan="1" colspan="1">26</td><td valign="top" align="center" rowspan="1" colspan="1">44.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Internet research</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td valign="top" align="center" rowspan="1" colspan="1">8.6</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Medical school curriculum</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">5.2</td></tr><tr><td valign="top" align="left" rowspan="5" colspan="1">How frequently do you use propranolol?</td><td valign="top" align="left" rowspan="1" colspan="1">Frequently (a few times a month)</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td valign="top" align="center" rowspan="1" colspan="1">8.6</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Occasionally (once a month or less)</td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">24.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Once</td><td valign="top" align="center" rowspan="1" colspan="1">16</td><td valign="top" align="center" rowspan="1" colspan="1">27.6</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Only pre-examinations</td><td valign="top" align="center" rowspan="1" colspan="1">17</td><td valign="top" align="center" rowspan="1" colspan="1">29.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Regularly (weekly or more)</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">10.3</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Have you noticed any improvements in academic performance when using propranolol?</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">35</td><td valign="top" align="center" rowspan="1" colspan="1">60.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">23</td><td valign="top" align="center" rowspan="1" colspan="1">39.7</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Was propranolol prescribed to you by a health care professional?</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">24</td><td valign="top" align="center" rowspan="1" colspan="1">41.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">34</td><td valign="top" align="center" rowspan="1" colspan="1">58.6</td></tr><tr><td valign="top" align="left" rowspan="5" colspan="1">Dosage</td><td valign="top" align="left" rowspan="1" colspan="1">5 mg</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1.7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">10 mg</td><td valign="top" align="center" rowspan="1" colspan="1">42</td><td valign="top" align="center" rowspan="1" colspan="1">72.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">20 mg</td><td valign="top" align="center" rowspan="1" colspan="1">7</td><td valign="top" align="center" rowspan="1" colspan="1">12.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">40 mg</td><td valign="top" align="center" rowspan="1" colspan="1">7</td><td valign="top" align="center" rowspan="1" colspan="1">12.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Missing data</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1.7</td></tr><tr><td valign="top" align="left" rowspan="5" colspan="1">How effective do you find propranolol in managing your symptoms?</td><td valign="top" align="left" rowspan="1" colspan="1">Extremely effective</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">10.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Very effective</td><td valign="top" align="center" rowspan="1" colspan="1">21</td><td valign="top" align="center" rowspan="1" colspan="1">36.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Effective</td><td valign="top" align="center" rowspan="1" colspan="1">21</td><td valign="top" align="center" rowspan="1" colspan="1">36.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Somewhat effective</td><td valign="top" align="center" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">13.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Not effective at all</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">3.4</td></tr><tr><td valign="top" align="left" rowspan="4" colspan="1">How long before a stressful event do you usually take propranolol?</td><td valign="top" align="left" rowspan="1" colspan="1">Less than 30 min</td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">24.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">30&#x02013;60 min</td><td valign="top" align="center" rowspan="1" colspan="1">25</td><td valign="top" align="center" rowspan="1" colspan="1">43.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1&#x02013;2 h</td><td valign="top" align="center" rowspan="1" colspan="1">16</td><td valign="top" align="center" rowspan="1" colspan="1">27.6</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">More than 2 h</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">5.2</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Have you ever experienced any side effects from propranolol?</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">21</td><td valign="top" align="center" rowspan="1" colspan="1">36.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">37</td><td valign="top" align="center" rowspan="1" colspan="1">63.8</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Are you aware of the potential risks of long-term use of propranolol?</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">43</td><td valign="top" align="center" rowspan="1" colspan="1">74.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">15</td><td valign="top" align="center" rowspan="1" colspan="1">25.9</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Would you recommend propranolol use to others?</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">28</td><td valign="top" align="center" rowspan="1" colspan="1">48.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">30</td><td valign="top" align="center" rowspan="1" colspan="1">51.7</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Do you feel adequately informed about propranolol and its effects?</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">39</td><td valign="top" align="center" rowspan="1" colspan="1">67.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">19</td><td valign="top" align="center" rowspan="1" colspan="1">32.8</td></tr><tr><td valign="top" align="left" rowspan="5" colspan="1">What is the primary reason for your propranolol use?<xref rid="t4fna" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Exam stress</td><td valign="top" align="center" rowspan="1" colspan="1">35</td><td valign="top" align="center" rowspan="1" colspan="1">60.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Anxiety management</td><td valign="top" align="center" rowspan="1" colspan="1">38</td><td valign="top" align="center" rowspan="1" colspan="1">65.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Public speaking</td><td valign="top" align="center" rowspan="1" colspan="1">13</td><td valign="top" align="center" rowspan="1" colspan="1">22.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Palpitations</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">5.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Other</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td valign="top" align="center" rowspan="1" colspan="1">8.6</td></tr><tr><td valign="top" align="left" rowspan="6" colspan="1">What side effects have you experienced?<xref rid="t4fna" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Dizziness</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="center" rowspan="1" colspan="1">50</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nausea</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">13.6</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cold hands</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">4.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fatigue</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="center" rowspan="1" colspan="1">50</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bradycardia</td><td valign="top" align="center" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">36.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sleep problems</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">4.5</td></tr></tbody></table><table-wrap-foot><fn id="t4fna"><p><sup>a</sup>Multiple answers were selected, percentage refers to percent of cases.</p></fn></table-wrap-foot></table-wrap><p><xref rid="F1" ref-type="fig">Figure 1</xref> shows the most common side effects experienced by propranolol users, with dizziness and fatigue being the two most common side effects, each affecting 50% of users who experienced side effects, followed by bradycardia (36.4%) as the second most common side effect. <xref rid="F2" ref-type="fig">Figure 2</xref> shows the primary reported reasons for propranolol use, with the most common being anxiety management (65.5%), followed by exam stress (60.3%) and public speaking (22.4%).</p><fig position="float" id="F1"><label>FIGURE 1</label><caption><p>Side effects experienced by propranolol user.</p></caption><graphic xlink:href="fmed-12-1586068-g001" position="float"/></fig><fig position="float" id="F2"><label>FIGURE 2</label><caption><p>Primary reported reasons for propranolol user.</p></caption><graphic xlink:href="fmed-12-1586068-g002" position="float"/></fig></sec></sec><sec sec-type="discussion" id="S4"><title>Discussion</title><p>This cross-sectional study was conducted at the University of Jordan to investigate the prevalence of propranolol use among students enrolled in the schools of Medicine and Dentistry. There is no prior research from Jordan about this research topic. Thus, our study builds on prior research which primarily took place in other Middle Eastern universities, exploring similar demographics (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B22" ref-type="bibr">22</xref>&#x02013;<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>). Propranolol has emerged as a significant pharmaceutical agent, primarily intended for the control of cardiac-related disorders. Beyond the primary use of the drug, certain BBs are lipophilic and can cross the blood-brain barrier (<xref rid="B6" ref-type="bibr">6</xref>). This mechanism of action renders it effective in relieving anxiety symptoms.</p><p>Our study revealed a relatively low adoption of propranolol among medical and dentistry students (9.9%) which contrasts with the findings by Al-Mohrej et al. at a university in Jeddah, Saudi Arabia, which reported a higher adoption rate of 30%. However, our results align with the findings of Alkhatabi et al. (<xref rid="B26" ref-type="bibr">26</xref>) which conducted a study in King Saud Bin Abdul Aziz University for Health Sciences and found the prevalence of propranolol to be 14.4% among medical students. Our findings are also consistent with a study conducted by Aljahdali et al., among health sciences students at Umm Al-Qura University in Makkah, Saudi Arabia that found 6.5% off-label use of propranolol (<xref rid="B22" ref-type="bibr">22</xref>). Another cross-sectional study conducted by Tounsi et al., in Riyadh dental schools found that nearly 12% of dental students used propranolol for non-medical reasons (<xref rid="B32" ref-type="bibr">32</xref>).</p><p>Our results showed that demographics such as gender and study program were not significantly associated with the use of propranolol, according to our yielded <italic>p</italic>-values of 0.938 and 0.164, respectively. Even after multivariate analysis and taking confounding variables into account, the predictors remained insignificant. This is consistent with the findings of a previous study by Altalhi et al. (<xref rid="B23" ref-type="bibr">23</xref>) that targeted medical students in all the districts of Saudi Arabia.</p><p>Our findings indicated that propranolol use was most prevalent among students in their clinical years, while none of the first-year students reported using the drug. This aligns with the research results of Abukhalaf et al. (<xref rid="B25" ref-type="bibr">25</xref>), Altalhi et al. (<xref rid="B23" ref-type="bibr">23</xref>), and Alkhatabi et al. (<xref rid="B26" ref-type="bibr">26</xref>) which showed an increase in propranolol use during the clinical years of undergraduate medical education. The results of previous studies showed a striking correlation between off-label use of propranolol with the stress associated to Objectively Structured Clinical Examination (OSCE) (<xref rid="B22" ref-type="bibr">22</xref>&#x02013;<xref rid="B26" ref-type="bibr">26</xref>). According to a previous study on medical students&#x02019; views of various examinations and assessment methods, 63% of participants indicated that OSCE was extremely stressful for them, and 50% said the assigned time for OSCE gave them short period for studying (<xref rid="B36" ref-type="bibr">36</xref>). The most conspicuous uses for propranolol in Alkhatabi et al., study revolved around exam anxiety relief and performance enhancement for OSCEs (70.6%), and before oral presentations (38.2%) (<xref rid="B26" ref-type="bibr">26</xref>). Similar results were reported by Al-Mohrej et al. (<xref rid="B24" ref-type="bibr">24</xref>) who found anxiety reduction to be the most common reason for use. This effectiveness in alleviating anxiety symptoms is related to the aforementioned ability of propranolol to exert its effect on the CNS (<xref rid="B8" ref-type="bibr">8</xref>). However, this also carries the risk of adverse effects that span from dizziness, fatigue, bradycardia to life-threatening rebound angina, arrhythmias and infarction (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>Almost half of the propranolol users in our study recommended the medication to other students, independently of experiencing side effects. This behavior may be attributed to medical students&#x02019; tendency to self-medicate, as highlighted by Pandya et al., where 82.3% of medical students reported self-medication within the last year (<xref rid="B37" ref-type="bibr">37</xref>). This is also consistent with the results of a study conducted by El Ezz et al. at Ain Shams University, Egypt, that found 55% prevalence of self-medication among medical students. From these, 60% increased the dose without medical advice and 4.8% reported side effects (<xref rid="B35" ref-type="bibr">35</xref>). Similarly, our study found that 58.6% of the propranolol users took it without a prescription from a healthcare professional. This could be explained by the fact that most students (93.1%) in our study were aware of propranolol&#x02019;s effect on anxiety and stress. This made them more likely to use the medication as evidenced by a statistically significant <italic>p</italic>-value of &#x0003c; 0.001, which remained significant after conducting a multivariate analysis that accounted for confounding variables such as program and academic level. A study by Pandya et al. (<xref rid="B37" ref-type="bibr">37</xref>) found a significant relationship between the level of education and heightened exam stress with the increased the likelihood of self-medication. The most prevalent reasons for this were documented as timesaving and convenience, which are crucial considerations in the lives of medical and dentistry students.</p><p>Although our study found no significant relationship between GPA and propranolol use (<italic>p</italic>-value 0.901), most students (60.3%) reported feeling like propranolol enhanced their academic performance. Propranolol is significantly associated with improved examination performance including mental arithmetic and verbal reasoning scores, especially among students with anxiety (<xref rid="B38" ref-type="bibr">38</xref>). A National Survey of 3,326 medical and pharmacy students in Saudi Arabia found that students who are taking BBs are those at high risk of underlying anxiety disorders (<xref rid="B34" ref-type="bibr">34</xref>). This can be attributed to propranolol&#x02019;s efficacy in providing relief to students in stress-induced environments like examinations (<xref rid="B7" ref-type="bibr">7</xref>). However, it is essential to acknowledge the possible placebo effect in the perceived effectiveness of BBs in managing stress among students. Despite a substantial portion of our population reporting that they felt propranolol was effective in alleviating their anxiety symptoms, the systematic review by Archer et al., shows a lack of tangible evidence that supports the effectiveness of BBs in managing anxiety (<xref rid="B39" ref-type="bibr">39</xref>). The absence of definitive efficacy suggests that the reported improvement by some users could potentially be influenced by their expectations of the anxiolytic effects rather than direct pharmacological effects (<xref rid="B39" ref-type="bibr">39</xref>). This is also supported by our findings that showed no statistically significant association between GPA and propranolol use.</p><sec id="S4.SS1"><title>Limitations</title><p>Not all the factors that could be associated with propranolol misuse were addressed in this study. The primary focus was on sociodemographic aspects, while psychological or clinical motivations behind the students&#x02019; decisions to use propranolol were not explored. Binary outcomes simplified the data analysis and allowed for the application of logistic regression, chi-square tests, and binary classification algorithms. This provided valuable insights and enhanced the interpretability of the results. However, there is potential for imbalanced results and biased predictions. Our findings should be interpreted within the context of a number of limitations. Firstly, we used convenience sampling, and all the participants were from the University of Jordan. This may impact the generalizability of our results to the broader population of Jordanian medical students. Secondly, the study&#x02019;s cross-sectional design is inherently associated with a number of drawbacks including snap-shot prevalence results and inability to establish temporal relationships or causality. Thirdly, the data was collected using an online self-administered questionnaire. Despite its validation from the literature, self-reported measures are subject to social desirability bias, recall bias, or neutral bias. Finally, we acknowledge that Hosmer-Lemeshow goodness-of-fit weaknesses of limited power and poor interpretability (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>).</p></sec><sec id="S4.SS2"><title>Recommendations</title><p>To improve the quality of future studies it is recommended to use a randomized sampling method to reduce bias. Additionally, upcoming research should be conducted in several private and public medical schools to allow for better comparisons and critical assessment of the findings to enhance generalizability and improve validity. Moreover, the issue of propranolol use without adequate medical supervision needs to be addressed. Our study reported that students, despite being aware of the side effects, continue to use as well as recommend propranolol to others. This raises concerns regarding the potential long-term side effects of the drug. Students must be educated on the dangers of self-medication regardless of their level of medical knowledge. Therefore, we recommend that educational initiatives be placed to educate students on the harmful effects of self-medication. Universities should also offer anxiety-management courses to help students find healthier ways to cope with academic-induced anxiety.</p></sec></sec><sec sec-type="conclusion" id="S5"><title>Conclusion</title><p>In this study, the prevalence of propranolol use was found to be 9.9%. Despite the high level of awareness about the possible side effects of propranolol, self-medication with propranolol by medical and dental students was prevalent. Among the students using propranolol, 58.6% took the medication without any supervision. Self-medication for the management of anxiety-related symptoms was evident, and it should not be taken lightly, especially when dealing with medications such as propranolol. The causal associations between potential sociodemographic and academic determinants with the inappropriate use of propranolol should be addressed through longitudinal studies. There is also a need for qualitative research to better understand the underlying reasons behind the inappropriate use of propranolol. This is necessary for designing context sensitive programs to address the problem of self-medication and to improve students&#x02019; management of anxiety and academic pressure.</p></sec></body><back><ack><p>The authors would like to thank Ms. Salma Farah, Ms. Joud AlShawish, Mr. Mahmoud Hamad, Ms. Joud AbuKhass, Ms. Zainab Alsayes, Ms. Boshra Da&#x02019;ameh, Ms. Enas Aljeezawe, Ms. Maya Saleh, and Ms. Hazar Alaabed for their contribution in collecting the data for this study.</p></ack><sec sec-type="data-availability" id="S6"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="S7"><title>Ethics statement</title><p>The studies involving humans were approved by the University of Jordan Institutional Review Board (IRB) (approval number 19/2024/781). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="S8"><title>Author contributions</title><p>HT: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Writing &#x02013; original draft, Writing &#x02013; review and editing. SA: Conceptualization, Writing &#x02013; review and editing, Software, Investigation, Methodology, Formal Analysis, Writing &#x02013; original draft, Data curation. AA: Software, Writing &#x02013; original draft, Writing &#x02013; review and editing, Investigation, Formal Analysis, Data curation, Methodology, Conceptualization. SS: Formal Analysis, Writing &#x02013; review and editing, Methodology, Data curation, Software, Conceptualization, Investigation, Writing &#x02013; original draft. YA: Writing &#x02013; review and editing, Formal Analysis, Conceptualization, Data curation, Software, Writing &#x02013; original draft, Investigation, Methodology. LA: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Software, Writing &#x02013; original draft, Writing &#x02013; review and editing. AE: Investigation, Conceptualization, Software, Writing &#x02013; review and editing, Writing &#x02013; original draft, Data curation, Formal Analysis, Methodology. RM: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Software, Writing &#x02013; original draft, Writing &#x02013; review and editing. SMA: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Writing &#x02013; original draft, Writing &#x02013; review and editing.</p></sec><sec sec-type="COI-statement" id="S10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="S11"><title>Generative AI statement</title><p>The authors declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="S12"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>J</given-names></name><name><surname>Crowther</surname><given-names>A</given-names></name><name><surname>Shanks</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>L</given-names></name><name><surname>Dornhorst</surname><given-names>A</given-names></name></person-group>. <article-title>A new Adenergic: Beta-receptor antagonist.</article-title>
<source><italic>Lancet.</italic></source> (<year>1964</year>) <volume>283</volume>:<fpage>1080</fpage>&#x02013;<lpage>1</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(64)91275-9</pub-id>
<pub-id pub-id-type="pmid">14132613</pub-id>
</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srinivasan</surname><given-names>AV</given-names></name></person-group>. <article-title>Propranolol: A 50-year historical perspective.</article-title>
<source><italic>Ann Indian Acad Neurol.</italic></source> (<year>2019</year>) <volume>22</volume>:<fpage>21</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.4103/Aian.AIAN_201_18</pub-id>
<pub-id pub-id-type="pmid">30692755</pub-id>
</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Routledge</surname><given-names>P</given-names></name><name><surname>Shand</surname><given-names>D</given-names></name></person-group>. <article-title>Clinical pharmacokinetics of propranolol.</article-title>
<source><italic>Clin Pharmacokinet.</italic></source> (<year>1979</year>) <volume>4</volume>:<fpage>73</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.2165/00003088-197904020-00001</pub-id>
<pub-id pub-id-type="pmid">378502</pub-id>
</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbar</surname><given-names>S</given-names></name><name><surname>Alorainy</surname><given-names>M</given-names></name></person-group>. <article-title>The current status of beta blockers&#x02019; use in the management of hypertension.</article-title>
<source><italic>Saudi Med J.</italic></source> (<year>2014</year>) <volume>35</volume>:<fpage>1307</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">25399206</pub-id>
</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shahrokhi</surname><given-names>M</given-names></name><name><surname>Gupta</surname><given-names>V</given-names></name></person-group>. <article-title>Propranolol.</article-title>
<source><italic>In: StatPearls.</italic></source>
<publisher-loc>Treasure Island (FL)</publisher-loc>: <publisher-name>StatPearls Publishing</publisher-name> (<year>2023</year>).</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cojocariu</surname><given-names>S</given-names></name><name><surname>Ma&#x0015f;taleru</surname><given-names>A</given-names></name><name><surname>Sasc&#x00103;u</surname><given-names>R</given-names></name><name><surname>St&#x00103;tescu</surname><given-names>C</given-names></name><name><surname>Mitu</surname><given-names>F</given-names></name><name><surname>Leon-Constantin</surname><given-names>M</given-names></name></person-group>. <article-title>Neuropsychiatric consequences of lipophilic beta-blockers.</article-title>
<source><italic>Medicina (B Aires).</italic></source> (<year>2021</year>) <volume>57</volume>:<fpage>155</fpage>. <pub-id pub-id-type="doi">10.3390/medicina57020155</pub-id>
<pub-id pub-id-type="pmid">33572109</pub-id>
</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szeleszczuk</surname><given-names>&#x00141;</given-names></name><name><surname>Fr&#x00105;czkowski</surname><given-names>D</given-names></name></person-group>. <article-title>Propranolol versus other selected drugs in the treatment of various types of anxiety or stress, with particular reference to stage fright and post-traumatic stress disorder.</article-title>
<source><italic>Int J Mol Sci.</italic></source> (<year>2022</year>) <volume>23</volume>:<fpage>10099</fpage>. <pub-id pub-id-type="doi">10.3390/ijms231710099</pub-id>
<pub-id pub-id-type="pmid">36077489</pub-id>
</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patten</surname><given-names>S</given-names></name></person-group>. <article-title>Propranolol and depression: Evidence from the antihypertensive trials.</article-title>
<source><italic>Can J Psychiatry.</italic></source> (<year>1990</year>) <volume>35</volume>:<fpage>257</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1177/070674379003500312</pub-id>
<pub-id pub-id-type="pmid">2140288</pub-id>
</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Xiang</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Intolerable side effects during propranolol therapy for infantile hemangioma: Frequency, risk factors and management.</article-title>
<source><italic>Sci Rep.</italic></source> (<year>2018</year>) <volume>8</volume>:<fpage>4264</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-22787-8</pub-id>
<pub-id pub-id-type="pmid">29523832</pub-id>
</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toubasi</surname><given-names>A</given-names></name><name><surname>Khraisat</surname><given-names>B</given-names></name><name><surname>AbuAnzeh</surname><given-names>R</given-names></name><name><surname>Kalbouneh</surname><given-names>H</given-names></name></person-group>. <article-title>A cross sectional study: The association between sleeping quality and stress among second and third medical students at the University of Jordan.</article-title>
<source><italic>Int J Psychiatry Med.</italic></source> (<year>2022</year>) <volume>57</volume>:<fpage>134</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1177/00912174211011287</pub-id>
<pub-id pub-id-type="pmid">33870751</pub-id>
</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>A</given-names></name><name><surname>Feely</surname><given-names>J</given-names></name></person-group>. <article-title>Pharmacokinetic drug interactions with propranolol.</article-title>
<source><italic>Clin Pharmacokinet.</italic></source> (<year>1983</year>) <volume>8</volume>:<fpage>253</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.2165/00003088-198308030-00004</pub-id>
<pub-id pub-id-type="pmid">6342901</pub-id>
</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiersinga</surname><given-names>W</given-names></name></person-group>. <article-title>Propranolol and thyroid hormone metabolism.</article-title>
<source><italic>Thyroid.</italic></source> (<year>1991</year>) <volume>1</volume>:<fpage>273</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1089/thy.1991.1.273</pub-id>
<pub-id pub-id-type="pmid">1688102</pub-id>
</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bushra</surname><given-names>R</given-names></name><name><surname>Aslam</surname><given-names>N</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name></person-group>. <article-title>Food-drug interactions.</article-title>
<source><italic>Oman Med J.</italic></source> (<year>2011</year>) <volume>26</volume>:<fpage>77</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.5001/omj.2011.21</pub-id>
<pub-id pub-id-type="pmid">22043389</pub-id>
</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amundson</surname><given-names>D</given-names></name><name><surname>Brodine</surname><given-names>S</given-names></name></person-group>. <article-title>A fatal case of propranolol poisoning.</article-title>
<source><italic>Drug Intell Clin Pharm.</italic></source> (<year>1988</year>) <volume>22</volume>:<fpage>781</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1177/106002808802201009</pub-id>
<pub-id pub-id-type="pmid">3229344</pub-id>
</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jouvent</surname><given-names>R</given-names></name><name><surname>Baruch</surname><given-names>P</given-names></name><name><surname>Simon</surname><given-names>P</given-names></name></person-group>. <article-title>Manic episode after propranolol withdrawal.</article-title>
<source><italic>Am J Psychiatry.</italic></source> (<year>1986</year>) <volume>143</volume>:<fpage>1633</fpage>. <pub-id pub-id-type="doi">10.1176/ajp.143.12.aj143121633</pub-id>
<pub-id pub-id-type="pmid">3789224</pub-id>
</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golden</surname><given-names>R</given-names></name><name><surname>Hoffman</surname><given-names>J</given-names></name><name><surname>Falk</surname><given-names>D</given-names></name><name><surname>Provenzale</surname><given-names>D</given-names></name><name><surname>Curtis</surname><given-names>T</given-names></name></person-group>. <article-title>Psychoses associated with propranolol withdrawal.</article-title>
<source><italic>Biol Psychiatry.</italic></source> (<year>1989</year>) <volume>25</volume>:<fpage>351</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/0006-3223(89)90182-0</pub-id>
<pub-id pub-id-type="pmid">2914157</pub-id>
</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rangno</surname><given-names>R</given-names></name><name><surname>Langlois</surname><given-names>S</given-names></name></person-group>. <article-title>Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol.</article-title>
<source><italic>Br J Clin Pharmacol.</italic></source> (<year>1982</year>) <volume>13</volume>:<fpage>345S</fpage>&#x02013;<lpage>51S</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2125.1982.tb01939.x</pub-id>
<pub-id pub-id-type="pmid">6125187</pub-id>
</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>R</given-names></name><name><surname>Olson</surname><given-names>H</given-names></name><name><surname>Amsterdam</surname><given-names>E</given-names></name><name><surname>Mason</surname><given-names>D</given-names></name></person-group>. <article-title>Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy.</article-title>
<source><italic>N Engl J Med.</italic></source> (<year>1975</year>) <volume>293</volume>:<fpage>416</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM197508282930902</pub-id>
<pub-id pub-id-type="pmid">1097925</pub-id>
</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><collab>College Music Symposium</collab>. <source><italic>The Ethics and Legality of Beta Blockers for Performance Anxiety: What Every Educator Should Know.</italic></source> (<year>2025</year>). Available online at: <ext-link xlink:href="https://symposium.music.org/51/item/18-the-ethics-and-legality-of-beta-blockers-for-performance-anxiety-what-every-educator-should-know.html" ext-link-type="uri">https://symposium.music.org/51/item/18-the-ethics-and-legality-of-beta-blockers-for-performance-anxiety-what-every-educator-should-know.html</ext-link>
<comment>(accessed March 24, 2025)</comment>.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strawn</surname><given-names>J</given-names></name><name><surname>Geracioti</surname><given-names>L</given-names></name><name><surname>Rajdev</surname><given-names>N</given-names></name><name><surname>Clemenza</surname><given-names>K</given-names></name><name><surname>Levine</surname><given-names>A</given-names></name></person-group>. <article-title>Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: An evidence-based treatment review.</article-title>
<source><italic>Expert Opin Pharmacother.</italic></source> (<year>2018</year>) <volume>19</volume>:<fpage>1057</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1080/14656566.2018.1491966</pub-id>
<pub-id pub-id-type="pmid">30056792</pub-id>
</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butt</surname><given-names>J</given-names></name><name><surname>Dalsgaard</surname><given-names>S</given-names></name><name><surname>Torp-Pedersen</surname><given-names>C</given-names></name><name><surname>K&#x000f8;ber</surname><given-names>L</given-names></name><name><surname>Gislason</surname><given-names>G</given-names></name><name><surname>Kruuse</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Beta-blockers for exams identify students at high risk of psychiatric morbidity.</article-title>
<source><italic>J Child Adolesc Psychopharmacol.</italic></source> (<year>2017</year>) <volume>27</volume>:<fpage>266</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1089/cap.2016.0079</pub-id>
<pub-id pub-id-type="pmid">27782771</pub-id>
</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aljahdali</surname><given-names>S</given-names></name><name><surname>Badr</surname><given-names>R</given-names></name><name><surname>Alotaibi</surname><given-names>M</given-names></name><name><surname>Alhelali</surname><given-names>S</given-names></name><name><surname>Abdullatif</surname><given-names>G</given-names></name><name><surname>Alshanberi</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Propranolol use among healthcare students in Saudi Arabia.</article-title>
<source><italic>Cureus.</italic></source> (<year>2023</year>) <volume>15</volume>:<fpage>e48606</fpage>. <pub-id pub-id-type="doi">10.7759/cureus.48606</pub-id>
<pub-id pub-id-type="pmid">38090443</pub-id>
</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altalhi</surname><given-names>F</given-names></name><name><surname>Alqadheeb</surname><given-names>A</given-names></name><name><surname>Alanazi</surname><given-names>F</given-names></name><name><surname>Almalki</surname><given-names>Z</given-names></name><name><surname>Alotaibi</surname><given-names>L</given-names></name><name><surname>Alghamdi</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>The prevalence of beta-blocker use among medical students in Saudi Arabia.</article-title>
<source><italic>Int J Med Dev Ctries.</italic></source> (<year>2024</year>) <volume>8</volume>:<fpage>666</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.24911/IJMDC.51-1702817628</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Mohrej</surname><given-names>O</given-names></name><name><surname>Al-Bani</surname><given-names>W</given-names></name><name><surname>AlShaalan</surname><given-names>N</given-names></name><name><surname>Aldahash</surname><given-names>R</given-names></name><name><surname>Alyamani</surname><given-names>A</given-names></name><name><surname>Almodaimegh</surname><given-names>H</given-names></name></person-group>. <article-title>Prevalence of self-prescribing propranolol among medical and dental students in riyadh, Saudi Arabia: A cross-sectional study.</article-title>
<source><italic>Heal Prof Educ.</italic></source> (<year>2018</year>) <volume>4</volume>:<fpage>16</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.hpe.2016.10.001</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abukhalaf</surname><given-names>A</given-names></name><name><surname>Alomar</surname><given-names>A</given-names></name><name><surname>Alsalame</surname><given-names>N</given-names></name><name><surname>Sumaya</surname><given-names>O</given-names></name><name><surname>Alessa</surname><given-names>O</given-names></name><name><surname>Alasbali</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Inappropriate use of beta-blockers among medical and dental students at King Saud University, Riyadh.</article-title>
<source><italic>J Fam Med Prim Care.</italic></source> (<year>2020</year>) <volume>9</volume>:<fpage>4391</fpage>. <pub-id pub-id-type="doi">10.4103/jfmpc.jfmpc_696_20</pub-id>
<pub-id pub-id-type="pmid">33110866</pub-id>
</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alkhatabi</surname><given-names>R</given-names></name><name><surname>Alowfi</surname><given-names>J</given-names></name><name><surname>Arshad</surname><given-names>L</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name></person-group>. <article-title>The prevalence of beta-blocker use among medical students at king Saud bin Abdulaziz university for health sciences in Jeddah, Saudi Arabia: A cross-sectional study.</article-title>
<source><italic>Cureus.</italic></source> (<year>2020</year>) <volume>12</volume>:<fpage>e11450</fpage>. <pub-id pub-id-type="doi">10.7759/cureus.11450</pub-id>
<pub-id pub-id-type="pmid">33329949</pub-id>
</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhadramy</surname><given-names>O</given-names></name><name><surname>Ahmad</surname><given-names>B</given-names></name><name><surname>Anam</surname><given-names>N</given-names></name><name><surname>Alhossini</surname><given-names>A</given-names></name></person-group>. <article-title>Prevalence and outcome of beta-blocker use during final exams among medical students.</article-title>
<source><italic>IJMDC.</italic></source> (<year>2020</year>) <volume>4</volume>:<fpage>2187</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.24911/IJMDC.51-1602943737</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masri</surname><given-names>R</given-names></name><name><surname>Kadhum</surname><given-names>M</given-names></name><name><surname>Farrell</surname><given-names>M</given-names></name><name><surname>Molodynski</surname><given-names>A</given-names></name></person-group>. <article-title>Wellbeing and mental health amongst medical students in Jordan: A descriptive study.</article-title>
<source><italic>Int Rev Psychiatry.</italic></source> (<year>2019</year>) <volume>31</volume>:<fpage>619</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1080/09540261.2019.1670402</pub-id>
<pub-id pub-id-type="pmid">31578112</pub-id>
</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarhan</surname><given-names>M</given-names></name><name><surname>Kelly</surname><given-names>J</given-names></name><name><surname>El-Farra</surname><given-names>N</given-names></name><name><surname>Rashid</surname><given-names>M</given-names></name></person-group>. <article-title>Collaborating for change: Reimagining medical education in Jordan through international partnerships.</article-title>
<source><italic>Discov Educ.</italic></source> (<year>2025</year>) <volume>4</volume>:<fpage>2</fpage>. <pub-id pub-id-type="doi">10.1007/s44217-024-00395-1</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><collab>The University of Jordan</collab>. <source><italic>School of Medicine.</italic></source> Available online at: <ext-link xlink:href="https://medicine.ju.edu.jo/Home.aspx" ext-link-type="uri">https://medicine.ju.edu.jo/Home.aspx</ext-link>
<comment>(accessed March 28, 2025)</comment>. (<year>2025</year>).</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranganathan</surname><given-names>P</given-names></name><name><surname>Caduff</surname><given-names>C</given-names></name><name><surname>Frampton</surname><given-names>C</given-names></name></person-group>. <article-title>Designing and validating a research questionnaire - Part 2.</article-title>
<source><italic>Perspect Clin Res.</italic></source> (<year>2024</year>) <volume>15</volume>:<fpage>42</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.4103/picr.picr_318_23</pub-id>
<pub-id pub-id-type="pmid">38282630</pub-id>
</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tounsi</surname><given-names>A</given-names></name><name><surname>Alnowaiser</surname><given-names>A</given-names></name><name><surname>Alsuhibani</surname><given-names>A</given-names></name><name><surname>Alsadhan</surname><given-names>L</given-names></name><name><surname>Hamdan</surname><given-names>H</given-names></name></person-group>. <article-title>Dental students&#x02019; attitude towards propranolol non-medical use: A multi-institutional cross-sectional study in Riyadh, Saudi Arabia.</article-title>
<source><italic>Eur J Dent Educ.</italic></source> (<year>2022</year>) <volume>26</volume>:<fpage>787</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1111/eje.12761</pub-id>
<pub-id pub-id-type="pmid">34951731</pub-id>
</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charan</surname><given-names>J</given-names></name><name><surname>Biswas</surname><given-names>T</given-names></name></person-group>. <article-title>How to calculate sample size for different study designs in medical research?</article-title>
<source><italic>Indian J Psychol Med.</italic></source> (<year>2013</year>) <volume>35</volume>:<fpage>121</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.4103/0253-7176.116232</pub-id>
<pub-id pub-id-type="pmid">24049221</pub-id>
</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsini</surname><given-names>A</given-names></name><name><surname>Alkhodaidi</surname><given-names>I</given-names></name><name><surname>Alsini</surname><given-names>Y</given-names></name><name><surname>Alsseeni</surname><given-names>S</given-names></name><name><surname>Alkhodaidi</surname><given-names>S</given-names></name><name><surname>Alsini</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>A national survey of self-prescription of beta-blockers and their relation to undiscovered anxiety among medical and pharmacological students in Saudi Arabia.</article-title>
<source><italic>Neuropsychiatr Dis Treat.</italic></source> (<year>2021</year>) <volume>17</volume>:<fpage>797</fpage>&#x02013;<lpage>807</lpage>. <pub-id pub-id-type="doi">10.2147/NDT.S289833</pub-id>
<pub-id pub-id-type="pmid">33762824</pub-id>
</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Ezz</surname><given-names>N</given-names></name><name><surname>Ez-Elarab</surname><given-names>H</given-names></name></person-group>. <article-title>Knowledge, attitude and practice of medical students towards self medication at Ain Shams University, Egypt.</article-title>
<source><italic>J Prev Med. Hyg</italic></source> (<year>2011</year>) <volume>52</volume>:<fpage>196</fpage>&#x02013;<lpage>200</lpage>.<pub-id pub-id-type="pmid">22442925</pub-id>
</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dadgar</surname><given-names>S</given-names></name><name><surname>Saleh</surname><given-names>A</given-names></name><name><surname>Bahador</surname><given-names>H</given-names></name><name><surname>Baradaran</surname><given-names>HR</given-names></name></person-group>. <article-title>OSCE as a tool for evaluation of practical semiology in comparison to MCQ &#x00026; oral examination.</article-title>
<source><italic>J Pak Med Assoc.</italic></source> (<year>2008</year>) <volume>58</volume>:<fpage>506</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">18846801</pub-id>
</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandya</surname><given-names>RN</given-names></name><name><surname>Jhaveri</surname><given-names>KS</given-names></name><name><surname>Vyas</surname><given-names>FI</given-names></name><name><surname>Patel</surname><given-names>VJ</given-names></name></person-group>. <article-title>Prevalence, pattern and perceptions of self-medication in medical students.</article-title>
<source><italic>Int J Basic Clin Pharmacol.</italic></source> (<year>2017</year>) <volume>2</volume>:<fpage>275</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.5455/2319-2003.ijbcp20130608</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drew</surname><given-names>P</given-names></name><name><surname>Barnes</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>S</given-names></name></person-group>. <article-title>The effect of acute beta-adrenoceptor blockade on examination performance.</article-title>
<source><italic>Br J Clin Pharmacol.</italic></source> (<year>1985</year>) <volume>19</volume>:<fpage>783</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2125.1985.tb02714.x</pub-id>
<pub-id pub-id-type="pmid">2862892</pub-id>
</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Archer</surname><given-names>C</given-names></name><name><surname>Wiles</surname><given-names>N</given-names></name><name><surname>Kessler</surname><given-names>D</given-names></name><name><surname>Turner</surname><given-names>K</given-names></name><name><surname>Caldwell</surname><given-names>D</given-names></name></person-group>. <article-title>Beta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis.</article-title>
<source><italic>J Affect Disord.</italic></source> (<year>2025</year>) <volume>368</volume>:<fpage>90</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2024.09.068</pub-id>
<pub-id pub-id-type="pmid">39271062</pub-id>
</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosmer</surname><given-names>D</given-names></name><name><surname>Hosmer</surname><given-names>T</given-names></name><name><surname>Le Cessie</surname><given-names>S</given-names></name><name><surname>Lemeshow</surname><given-names>S</given-names></name></person-group>. <article-title>A comparison of goodness-of-fit tests for the logistic regression model.</article-title>
<source><italic>Stat Med.</italic></source> (<year>1997</year>) <volume>16</volume>:<fpage>965</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1002/(sici)1097-0258(19970515)16:93.0.co;2-o</pub-id><pub-id pub-id-type="pmid">9160492</pub-id>
</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steyerberg</surname><given-names>E</given-names></name><name><surname>Vickers</surname><given-names>A</given-names></name><name><surname>Cook</surname><given-names>N</given-names></name><name><surname>Gerds</surname><given-names>T</given-names></name><name><surname>Gonen</surname><given-names>M</given-names></name><name><surname>Obuchowski</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Assessing the performance of prediction models: A framework for traditional and novel measures.</article-title>
<source><italic>Epidemiology.</italic></source> (<year>2010</year>) <volume>21</volume>:<fpage>128</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1097/EDE.0b013e3181c30fb2</pub-id>
<pub-id pub-id-type="pmid">20010215</pub-id>
</mixed-citation></ref></ref-list></back></article>